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J Sex MedIntroduction: The Hypogonadism Impact of Symptoms Questionnaire (HIS-Q) is a patient-reported outcome
measurement designed to comprehensively evaluate the symptoms of hypogonadism and to detect changes in
these symptoms in response to treatment.
Aim: To conduct item analysis and reduction, evaluate the psychometric properties of the HIS-Q, and provide
guidance on interpreting the instrument score.
Methods: A 12-week observational, longitudinal study of hypogonadal men was conducted. Participants
completed the HIS-Q every 2 weeks. Blood samples were collected to evaluate testosterone levels. Participants
also completed the Aging Male’s Symptoms Scale, the International Index of Erectile Function, the Short Form-
12 Health Survey, and the Patient-Reported Outcomes Measurement Information System Sexual Activity,
Satisfaction with Sex Life, Sleep Disturbance, and Applied Cognition Scales (at baseline and weeks 6 and 12).
Clinicians completed the Clinical Global Impression of Severity and Change measurements and a clinical form.
Main Outcome Measures: Individual item performance was evaluated using descriptive statistics and Rasch
analyses. Reliability (internal consistency and test-retest), validity (concurrent and know groups), and respon-
siveness were assessed.
Results: In total, 177 men participated in the study (mean age ¼ 54.1 years, range ¼ 23e83). The original
53-item draft HIS-Q was reduced to 28 items; the ﬁnal instrument included ﬁve domains (sexual, energy, sleep,
cognition, and mood) with two sexual subdomains (libido and sexual function). For all domains, test-retest
reliability was acceptable (intraclass correlation coefﬁcients > 0.70), construct validity was good (jr > 0.30j
for all comparisons). Known-groups validity was demonstrated for all HIS-Q domain scores, subdomain scores,
and the total score as measured by the Clinical Global Impression of Severity, and total testosterone level at
baseline (P < .05 for all comparisons). All domains and subdomains were responsive to change based on patient-
rated anchor questions (P < .05 for all comparisons).
Conclusion: The ﬁnal 28-item HIS-Q is reliable, valid, and responsive. The HIS-Q is suitable for inclusion in
future clinical trials to help characterize the effects of testosterone replacement therapy.
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1738 Gelhorn et alINTRODUCTION
Hypogonadism is associated with a range of symptoms,
including decreased libido, erectile dysfunction, decreased en-
ergy, sleep disturbance, and changes in mood.1 Many of these
symptoms are difﬁcult to evaluate clinically and are best assessed
through patient-reported outcome (PRO) measurements. There
are several existing PRO instruments that have been used to
evaluate the symptoms and effects of hypogonadism, such as the
Psychosexual Daily Questionnaire,2 the Aging Males Symptoms
Scale (AMS),3 the Sexual Arousal, Interest, and Drive Scale, and
the Hypogonadism Energy Diary.4 Although each of these in-
struments is useful in speciﬁc contexts, and some are well known,
each is limited in at least one way. Speciﬁcally, all were not
designed to assess hypogonadism comprehensively, have not
been validated, and/or have not been developed according to
regulatory standards.
The Hypogonadism Impact of Symptoms Questionnaire
(HIS-Q) is a PRO instrument that was designed to assess
changes in symptoms in hypogonadal men in response to
testosterone replacement therapy (TRT).5 The instrument was
developed primarily for use in clinical trial settings, has been
developed in accordance with the Food and Drug Administra-
tion’s PRO guidance for industry, and addresses the limitations
of existing instruments.6 Development was informed by a liter-
ature review, input from clinicians, and qualitative studies with
patients aimed at comprehensively identifying the symptoms of
the condition.5
The original draft HIS-Q was a 53-item questionnaire with a
conceptual framework that included sexual, physical signs and
symptoms, energy, sleep, cognitive, and mood domains. Results
from the initial qualitative work in hypogonadal patients indi-
cated that the HIS-Q was a comprehensive measurement of
hypogonadal symptoms in men. The HIS-Q reﬂected the varied
symptom experiences of patients, and the content validity of the
instrument was conﬁrmed.5METHODS
Aims
The present study was designed as a stand-alone, 12-week,
longitudinal, observational validation study of hypogonadal men
for informing item reduction, developing scoring and scaling,
and evaluating the psychometric properties of the HIS-Q. The
primary objective of this study was to develop a ﬁnal version of
the HIS-Q of appropriate length for use in clinical trials, with an
established scoring algorithm and acceptable psychometric
properties (ie, reliability, validity, and responsiveness).Participants
Twenty U.S. clinical sites participated in the study. Eligible
participants who signed informed consents included men who
were at least 18 years old; diagnosed with hypogonadism (serum
total testosterone concentration< 300 ng/dL before enrollment);switching TRT treatments or on maintenance therapy or were
treatment naïve; and able to understand English. Patients were
excluded if they had non-stabilized depression (stabilized was
deﬁned as on the same antidepressant medication at the same
dosage for 3 months), severe psychiatric illness, or addictions;
history of or current obstructive sleep apnea; a clinically signiﬁcant
medical condition; or taking a concurrent medication that would
affect hormonal balance or sexual functioning (eg, phosphodies-
terase type 5 inhibitors) or interfere with participants’ participa-
tion in the study.Procedures and Measurements
The study protocol and procedures used were reviewed and
approved by the appropriate institutional review committee
(Ethical and Independent Review Services Institutional Review
Board, September 25, 2013, protocol 13110-01). All study staff
at every site were trained using a standardized training protocol
on the purpose and procedures for the study. Participants
completed in-person study visits at baseline, week 2, and week
12. The ﬁrst assessment was completed during their ﬁrst in-clinic
visit (baseline), and subsequent assessments were completed at
home every 2 weeks from week 2 through week 12. All PRO
assessments were completed on an electronic PRO device. A
subset of participants also completed a daily diary from baseline
to day 28. The schedule of study assessments and a description of
each is presented in Table 1.3,7e11 Testosterone levels were
assessed through blood draws from all participants at baseline and
from participants who were beginning treatment or switching to
a different treatment at weeks 2 and 12. Blood serum samples
were processed and analyzed by a central laboratory (Total
Testosterone: AbbVie, Inc., North Chicago, IL, USA; Free
Testosterone: PPD Laboratories, Middleton, WI, USA) using
liquid chromatography and tandem mass spectrometry and
equilibrium dialysis to assess total and free testosterone levels,
respectively.Statistical Analyses
Descriptive statistics were used to characterize the socio-
demographic and clinical characteristics of the sample. Item-level
descriptive statistics (means, SD, median, range, frequency) were
used to evaluate the performance of individual HIS-Q items.
Then, exploratory factor analyses were used to analyze the factor
structure of the instrument. Rasch analyses12 were used to eval-
uate individual item and subscale properties. Exploratory factor
analyses and Rasch analyses were conducted using SAS (SAS
Institute, Cary, NC, USA) and RUMM2030,13 respectively.
These analyses were conducted iteratively and the results were
used to reduce the item pool and establish subscales and a
scoring algorithm for the reduced HIS-Q. Items were ﬂagged
for consideration as deletion candidates based on descriptive item
analyses (>50% ﬂoor and ceiling effects, high inter-item corre-
lations > 0.80 and/or low item-total correlations < 0.20), factor
analyses (weak factor loadings < 0.40, poor model ﬁt), andJ Sex Med 2016;13:1737e1749
Table 1. Study events schedule
Study events Mode Screening
Visit 1,
baseline
Visit 2,
week 2* Week 4† Week 6† Week 8† Week 10†
Visit 3,
week 12* Items, n Concepts measured
Interpretation
guidelines
Investigator/site
completed
Clinical form Paper U Patients’ clinical
characteristics
—
CGI-S Paper U U U Single
item
Physician’s overall
impression of
patient’s
hypogonadism
symptoms
Higher scores
indicate greater
severity
CGI-C Paper U U Single
item
Clinician’s perception of
change in symptoms
between study visits
—
Serum testosterone
testing
Blood
draw
U U‡ U‡ — —
Medical report form Paper Completed as needed to report any changes to a patient’s treatment or
testosterone levels§
— —
Patient completed
HIS-Q U U U U U U U 53 Sexual and physical signs
and symptoms,
energy, sleep,
cognition, and mood
Lower scores
indicate better
function and
fewer
symptoms
AMS3 Electronic U U U 17 Sleep difﬁculty, low
energy, physical
symptoms, effects on
sexual functioning and
mood
Lower scores
indicate better
functioning
IIEF7 Electronic U U U 15 Domains of sexual
function (erectile
dysfunction, orgasmic
function, sexual
desire, intercourse
satisfaction, and
overall satisfaction)
Higher scores
indicate less
dysfunction
PROMIS Interest in
Sexual Activity
Scale8
Electronic U U U 4 Sexual function,
including desire in
past 30 d
Higher scores
indicate more
interest in
sexual activity
PROMIS Global
Satisfaction With
Sex Life Scale8
Electronic U U U 7 Satisfaction with sex life
in past 30 d
Higher scores
indicate greater
satisfaction
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Table 1. Continued
Study events Mode Screening
Visit 1,
baseline
Visit 2,
week 2* Week 4† Week 6† Week 8† Week 10†
Visit 3,
week 12* Items, n oncepts measured
Interpretation
guidelines
PROMIS Sleep
Disturbance Scale9
Electronic U U U 8 erceptions of sleep
quality, sleep depth,
and restoration
associated with sleep
Higher scores
indicate greater
sleep
disturbance
PROMIS Applied
CognitioneAbilities:
(SF-8a)10
Electronic U U U 8 erceptions of cognitive
functioning and
changes in cognitive
abilities (eg,
concentration,
memory) over 7-d
period
Higher scores
indicate better
cognitive
functioning
SF-1211 Electronic U U U 12 unctional health and
well-being, physical
and mental health,
and health utility
during a typical day
and past 4 wk
Higher scores
indicate better
health status
Anchor questions Electronic U U U U U 9 exual activity, libido,
erectile functioning,
overall sexual
function, tiredness,
mood, cognitive
functioning, sleep, and
overall hypogonadism
condition
Higher scores
indicate better
functioning and
outcomes
Daily diaryk Electronic Daily from baseline to day
28
12 exual activity, erectile
function, energy,
sleep, cognition, and
mood
Higher scores
indicate greater
frequency or
more symptoms
AMS ¼ Aging Male’s Symptoms Scale; CGI-C ¼ Clinical Global ImpressioneChange; CGI-S ¼ Global ImpressioneSeverity; HIS-Q ¼ Hypogonadism I act of Symptoms Questionnaire; IIEF ¼ International
Index of Erectile Function; PROMIS ¼ Patient-Reported Outcomes Measurement Information System; SF-12 ¼ Short Form-12 Health Survey.
*At visits 1, 2, and 3, patients attended a study visit; however, all patient-reported outcome measurements for visits 2 and 3 were completed by patien at home, before the visit, at their regularly scheduled
time on the electronic patient-reported outcomes device.
†Patients did not come to the sites for study-related visits during these weeks but did complete study questionnaires on the electronic patient-reported utcomes device at home at each of these time points.
‡Only patients on new treatment had study-related blood draws at visits 2 and 3.
§Sites reported any additional serum testosterone blood sample results that were independent of the study blood draws at each visit.
kA subset of 60 patients completed a daily diary of questions related to the sexual activity domain and the other domains (energy, sleep, cognitiv mood) from baseline to day 28.
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Table 2. Sociodemographic characteristics (N ¼ 177)
Age (y)
Mean (SD) 54.1 (11.4)
Median (range) 55.0 (23.0e83.0)
Missing, n (%) 1 (0.6)
Race, n (%)*
Black or African American 32 (18.1)
White 131 (74.0)
Other† 7 (4.0)
Missing 7 (4.0)
Ethnicity, n (%)
Hispanic or Latino 9 (5.1)
Not Hispanic or Latino 166 (93.8)
Missing 2 (1.1)
Employment status, n (%)
Employed, full time 105 (59.3)
Employed, part time 12 (6.8)
Student 2 (1.1)
Unemployed, disabled, retired 52 (29.4)
Other‡ 5 (2.8)
Missing 1 (0.6)
Education, n (%)
Secondary, high school, some college,
trade school
88 (49.7)
College degree 58 (32.8)
Postgraduate degree 30 (16.9)
Missing 1 (0.6)
Currently in intimate relationship, n (%)
Yes 146 (82.5)
No 30 (16.9)
Missing 1 (0.6)
*Categories are not mutually exclusive.
†Asian (n ¼ 3), Native Hawaiian/Paciﬁc Islander (n ¼ 1), Hispanic (n ¼ 1),
Haitian (n ¼ 1), and Jamaican (n ¼ 1).
‡Self-employed (n ¼ 4) and sales (n ¼ 1).
Psychometric Evaluation of HIS-Q 1741Rasch analyses (item misﬁt, disordered thresholds). Item
reduction decisions also considered previous qualitative research
ﬁndings (ie, concept elicitation, content validity, etc) and input
from expert clinicians on the clinical relevance and importance
of items.
After item pool reduction and scoring algorithm establish-
ment, the psychometric properties of the HIS-Q were evaluated.
Internal consistency reliability of the HIS-Q domains was eval-
uated using the Cronbach a coefﬁcient14 at baseline, week 6, and
week 12, with reliability values of at least 0.70 denoting a more
homogeneous scale.15 Test-retest reliability was assessed using
intraclass correlation coefﬁcients and paired-sample t-tests for all
HIS-Q domain scores and the total score to examine HIS-Q
stability over time within a stable subsample. Stable subjects
were those with “no change” in relevant anchor questions and
Clinical Global Impression (CGI) for Change from baseline to
week 2; intraclass correlation coefﬁcients of at least 0.7 indicate
good test-retest reliability, coefﬁcients from 0.4 to 0.7 indicate
moderate test-retest reliability, and coefﬁcients less 0.4 indicated
low test-retest reliability.15,16
Convergent and divergent validity of the HIS-Q was assessed
using Pearson product-moment and Spearman rank correlation
coefﬁcients to estimate the relation between HIS-Q domains and
other conceptually relevant measurements (eg, higher correla-
tions among HIS-Q sexual domains and Patient-Reported
Outcomes Measurement Information System [PROMIS] and
AMS sexual scales, HIS-Q energy domain and AMS Somato-
Vegetative Scale and Short Form-12 Health Survey vitality
item, HIS-Q sleep domain and PROMIS sleep, HIS-Q cogni-
tion domain and PROMIS cognition, HIS-Q mood domain and
AMS psychological). To assess known-groups validity, mean
domain scores on the HIS-Q were analyzed by disease severity
(CGI for Severity) and total testosterone was analyzed by analysis
of variance.
Responder deﬁnitions were identiﬁed for the HIS-Q domains,
subdomains, and total score using anchor-based and distribution-
based methods. Mean scores for each HIS-Q domain and sub-
domain for participants who improved by one point on each
concept-speciﬁc anchor question were used to establish anchor-
based responder deﬁnitions. The SD at baseline (0.2, 0.3, and
0.5 times estimates) and the standard error of measurement17,18
were used to establish distribution-based responder deﬁnitions. A
triangulation process considering anchor- and distribution-based
deﬁnitions was used to derive ﬁnal responder deﬁnitions of
clinically meaningful change for each of the HIS-Q domain and
subdomain scores.RESULTS
In total, 196 patients were recruited into the study; a ﬁnal
analysis sample of 177 patients included all participants who had
HIS-Q and clinical data at baseline (baseline, n ¼ 177; week 2,
n ¼ 163; week 4, n ¼ 166; week 6, n ¼ 162; week 8, n ¼ 157;J Sex Med 2016;13:1737e1749week 10, n¼ 160; week 12, n¼ 156). Participants were recruited
from 20 clinical sites in 14 different states across the United States
(mean number of patients per site ¼ 9.9, SD ¼ 4.6). Participants
included 47 men who were new to TRT, 41 men who were
switching from one TRT to another, and 89 maintenance patients
who were on TRT at the time of enrollment and had no plans to
change their treatment.Demographics and Clinical Characteristics
Themean age of study participants was 54.1 years (SD¼ 11.4),
and most participants were white (74.0%) and were involved in an
intimate relationship (82.5%; Table 2). Average time since
hypogonadism diagnosis was 2.8 years (SD ¼ 2.2), with almost
half the study participants classiﬁed by their providers as having a
primary acquired etiology (45.8%; Table 3). Average body mass
index of the study sample was 30.2 (SD ¼ 5.2). Baseline mean
total and free testosterone levels for all tested participants were
507.6 ng/dL (SD ¼ 495.4) and 15.0 ng/dL (SD ¼ 15.9),
respectively.
Table 3. Baseline participant clinical characteristics—site reported
(N ¼ 177)
Time since initial diagnosis of
hypogonadism (y)
Mean (SD) [range] 2.2 (3.2) [0.0e20.56]
Unknown, n (%) 1 (0.6)
Provider-reported hypogonadism
etiology, n (%)
Primary congenital 23 (13.0)
Primary acquired 81 (45.8)
Secondary congenital 0 (0.0)
Secondary acquired 28 (15.8)
Combined 7 (4.0)
Unknown 38 (21.5)
Speciﬁc suspected etiology or
diagnosis, n (%)
Pituitary adenoma or disorder 2 (1.1)
Testicular trauma or disorder 2 (1.1)
Other* 19 (10.7)
Unknown 154 (87.0)
Chief complaint or presenting
symptom, n (%)
Erectile dysfunction 46 (26.0)
Low libido 45 (25.4)
Tiredness 29 (16.4)
Fatigue 48 (27.1)
Other† 5 (2.8)
Unknown 4 (2.3)
History of testosterone replacement
medications, n (%)
No history 52 (29.4)
Buccal 2 (1.13)
Topical 69 (39.0)
Patch 6 (3.4)
Subcutaneous pellet 20 (11.3)
Injection 69 (39.0)
Missing 1 (0.6)
Calculated BMI, mean (SD)
[range]‡
30.2 (5.2) [21.5e53.2]
Baseline serum total testosterone
concentration, n§
172
Concentration (ng/dL), mean
(SD) [range]
507.62 (495.37)
[19.70e4,160.00]
Missing, n (%) 5 (2.8)
Baseline free testosterone
concentration, n
149
Concentration (ng/dL), mean
(SD) [range]
15.00 (15.89)
[0.53e126.00]
Missing, n (%) 28 (15.8)
BMI ¼ body mass index.
*Senescence (n ¼ 13), obesity (n ¼ 2), aging (n ¼ 3), and testicular failure
(n ¼ 1).
†No symptom (n ¼ 1), poor concentration (n ¼ 1), low energy (n ¼ 1),
weakness (n ¼ 1), and weight gain (n ¼ 1).
‡BMI ¼ (weight [pounds]  703)/(height [inches])2.
§Baseline serum total testosterone concentration lower than 300 ng/dL
(n ¼ 68).
1742 Gelhorn et alBaseline AMS scores indicated that participants on mainte-
nance therapy had moderate levels of sexual impairment, whereas
patients who were switching medications or were treatment naïve
had severe sexual impairment (overall mean ¼ 11.7, SD ¼ 4.3,
range ¼ 5e23). Baseline AMS scores indicated moderate psy-
chological impairment (overall mean ¼ 8.7, SD ¼ 3.8) and
moderate somatic impairment (overall mean ¼ 15.1, SD ¼ 5.2).
Mean International Index of Erectile Function domain scores
indicated moderate to high dysfunction, with the highest
dysfunction demonstrated for the orgasmic function subscale
(mean ¼ 3.6 ± 2.8, range ¼ 0e10); moderate dysfunction was
observed for all other subscales (ie, erectile function, sexual
desire, intercourse satisfaction, and overall satisfaction). The
mean CGI for Severity value for the full sample at baseline was
3.5 (SD ¼ 1.1, range ¼ 1e6), indicating mild to moderate
hypogonadal symptom severity.
HIS-Q Item Evaluation and Item Reduction
The individual item-level analyses demonstrated acceptable
distribution of the HIS-Q item responses across response cate-
gories and good distributional characteristics. Minor issues
(eg, ﬂoor effects, high inter-item correlations, disordered
thresholds, poor ﬁt to the Rasch model) were noted for some
items and taken into consideration during item reduction. For
example, because expected items 15 (sexual activities enjoyable)
and 16 (sexual activities satisfying) and items 22 (tired) and 23
(physically tired) were each highly correlated with each other.
Thus, additional information (ie, factor loadings and Rasch
results) was used to select the best-performing item from each
pair. Other items performed poorly based on most item evalu-
ation criteria and were eliminated.
Initially, a 30-item revised version of the instrument was
established based on the item analyses; this included ﬁve nu-
merical response items on frequency of sexual activities and an
additional 25 ordinal response scale items in the sexual (n ¼ 7),
physical signs and symptoms (n ¼ 2), energy (n ¼ 3), sleep
(n ¼ 3), cognition (n ¼ 3), and mood (n ¼ 7) domains.
However, psychometric analyses on this 30-item version of the
HIS-Q indicated very poor psychometric characteristics for the
physical signs and symptoms domain, and the two items from
this domain were subsequently removed, yielding the ﬁnal
28-item HIS-Q (Supplementary Appendix A). This decision
was supported by the clinical experts who assessed aspects of
this domain using direct clinical measurements.
Factor Structure and Scoring for the Final 28-Item
HIS-Q
Exploratory factor analyses (n ¼ 133) suggested that the ﬁnal
HIS-Q is multifactorial. A ﬁve-factor solution yielded generally
high factor loadings for the items within the following domains
and subdomains (factor loading ranges: libido ¼ 0.50e0.68;
sexual function ¼ 0.51e0.87; energy ¼ 0.71e0.80; sleep ¼
0.37e0.68; and mood and cognition ¼ 0.31e0.68;J Sex Med 2016;13:1737e1749
Psychometric Evaluation of HIS-Q 1743Supplementary Table 1). The cognition domain did not emerge
as a distinct factor in this ﬁve-factor solution, but rather the
cognition items loaded with the mood items.
Instrument scoring includes each of the 23 ordinal response
scale items and yields ﬁve domain scores (sexual; energy, sleep,
cognition, and mood) and two sexual subdomain scores (libido
and sexual function). All 23 ordinal response scale items also can
be used to yield a HIS-Q total score. The domain, subdomain,
and total scores range from 0 to 100, with higher scores indi-
cating greater dysfunction. No scoring is needed for the ﬁrst ﬁve
questions, because the items capture numerical data related to
the frequency of sexual activity.Psychometric Evaluation of the Final 28-Item
HIS-Q
After item selection and development of the scoring algorithm,
the psychometric properties of the ﬁnal 28-item HIS-Q were
evaluated.
Rasch Analyses
Rasch analyses were conducted on each of the HIS-Q do-
mains and subdomains (n ¼ 117e171). Item performance was
very good, with all items demonstrating ﬁt to the Rasch model
(P > .05 for all comparisons) and good distributions of item
thresholds (libido, b ¼ 3.2 to 3.4; sexual function, b ¼ 2.4
to 7.49; energy, b ¼ 6.0 to 7.4; sleep, b ¼ 2.6 to 2.1;
cognition, b ¼ 3.2 to 2.1; mood, b ¼ 3.6 to 2.7). These
item thresholds were well matched to the distributions of in-
dividuals within each domain. There were a few minor issues
with disordered thresholds (ie, some item response categories did
not accurately distinguish between participants with different
levels of hypogonadism severity) for three items, including
“difﬁcult achieving erections,” “difﬁculty ejaculating,” and “sad.”
Reliability
The internal consistency reliability (ie, Cronbach a) was
very good for the sexual symptoms domain (baseline¼ 0.79, week
6 ¼ 0.80, week 12 ¼ 0.81), libido subdomain (baseline ¼ 0.74,
week 6 ¼ 0.73, week 12 ¼ 0.76), sexual function subdomain
(baseline ¼ 0.78, week 6 ¼ 0.80, week 12 ¼ 0.78), energy
domain (baseline¼ 0.91, week 6¼ 0.90, week 12¼ 0.90), mood
domain (baseline ¼ 0.85, week 6 ¼ 0.87, week 12 ¼ 0.89),
and HIS-Q total score (baseline ¼ 0.89, week 6 ¼ 0.91, week
12¼ 0.92). Internal consistency reliabilitywas slightly lower for the
cognition (range ¼ 0.65e0.72) and sleep (range ¼ 0.58e0.64)
domains.
Test-retest reliability was assessed in those who were deﬁned as
stable based on patient-reported anchor questions from baseline
to week 2. The ICCs were good for the sexual symptoms domain
(0.81), libido subdomain (0.77), sexual function subdomain
(0.80), energy domain (0.73), mood domain (0.87), and total
score (0.80). Test-retest reliability was acceptable for the sleep
(0.68) and cognition (0.68) domains.J Sex Med 2016;13:1737e1749Validity
There was strong evidence for convergent validity across all
scales. The sexual domain and libido and sexual function sub-
domains were strongly correlated with the AMS Sexual Scale
(r¼ 0.65, 0.55, 0.55, respectively, P< .0001 for all comparisons),
the International Index of Erectile Function Overall Satisfaction
Score (r ¼ 0.68, 0.44, 0.67, P < .0001 for all comparisons), the
PROMIS Sexual Activity Score (r ¼ 0.60, 0.74, 0.39,
P < .0001 for all comparisons), and the PROMIS Global Satis-
faction with Sex Life Score (r¼0.65,0.45,0.60, P< .0001
for all comparisons). The energy domain was strongly correlated
with the AMS Somato-Vegetative Scale (r ¼ 0.67, P < .0001)
and the Short Form-12 Health Survey Vitality item (r ¼ 0.62,
P < .0001). The sleep domain was strongly correlated with the
PROMIS Sleep Disturbance score (r ¼ 0.75, P < .0001), the
cognition domain was strongly correlated with the PROMIS
Applied Cognition score (r ¼ 0.72, P < .0001), and the mood
domain was strongly correlated with the AMS Psychological Scale
(r ¼ 0.78, P < .0001). Divergent validity was demonstrated
through low and non-signiﬁcant correlations among conceptually
unrelated scales (eg, HIS-Q energy, sleep, cognition, and mood
domains with International Index of Erectile Function Orgasmic
Function Scale; r ¼ 0.11e0.16).
The HIS-Q scores also were correlated with testosterone levels.
At baseline, there were moderate correlations between total
testosterone and the sexual domain (r ¼ 0.36, P < .0001), li-
bido subdomain (r ¼ 0.29, P < .001), sexual function domain
(r ¼ 0.32, P < .0001), energy domain (r ¼ 0.25, P < .001),
and HIS-Q total score (r ¼ 0.34, P < .0001). Smaller but
signiﬁcant correlations were observed between total testosterone
and sleep (r ¼ 0.17, P < .05), cognition (r ¼ 0.19, P < .05),
and mood (r ¼ 0.18, P < .05) domains. A similar pattern of
results with moderate correlations was observed between free
testosterone levels and sexual, libido, sexual function, energy, and
total scores (r ¼ 0.37 to 0.29, P < .001 for all comparisons).
Results demonstrated good known-group validity. All HIS-Q
scores were signiﬁcantly different when grouped according to
clinician ratings of severity (P < .05 for all comparisons), and
groups with greater clinician-rated severity also had signiﬁcantly
higher HIS-Q scores (Table 4). Similarly, when grouped by total
testosterone levels, signiﬁcantly higher HIS-Q scores were
observed in men with lower testosterone levels (P < .05 for all
comparisons; Table 4).Responsiveness
Changes in each of the patient-reported anchor questions were
reﬂected by signiﬁcant changes in the expected direction for all the
HIS-Q scales (P < .05 for all comparisons; Table 5). Respon-
siveness also was assessed using changes based on the CGI for
Severity; the sexual domain (P< .01), sexual function subdomain
(P < .01), energy domain (P < .05), and HIS-Q total score
(P< .01) showed signiﬁcant trends in the expected direction from
baseline to week 2 and from baseline to week 12 (Table 6).
Table 4. Known-groups validity
HIS-Q score
CGI-S symptom severity categories (N ¼ 177)
Overall F-test*
Pairwise comparison
(P value)†
No or very mild
symptoms Mild Moderate Severe
n LS mean (SE) n LS mean (SE) n LS mean (SE) n LS mean (SE) F P value
Sexual domain 34 30.99 (3.26) 35 41.73 (3.21) 73 46.78 (2.22) 30 57.86 (3.47) 11.29 <.0001 2k, 3#, 5k
Libido subdomain 34 38.24 (3.43) 36 46.99 (3.33) 73 48.74 (2.34) 30 56.94 (3.65) 4.76 .0033 3k
Sexual function subdomain 35 26.61 (4.26) 36 37.85 (4.20) 73 45.21 (2.95) 30 58.54 (4.60) 9.37 <.0001 2k, 3#, 5k
Energy domain 35 31.19 (4.02) 37 41.89 (3.91) 73 48.63 (2.78) 30 57.22 (4.34) 7.35 .0001 2k, 3{
Sleep domain 35 31.67 (3.19) 37 33.56 (3.10) 71 36.85 (2.24) 30 44.72 (3.45) 2.97 .0334
Cognition domain 35 25.24 (2.75) 36 30.32 (2.72) 73 36.76 (1.91) 30 43.33 (2.97) 7.95 <.0001 2k, 3{, 5k
Mood domain 35 23.16 (2.85) 37 31.18 (2.77) 72 35.81 (1.99) 30 41.67 (3.08) 7.40 .0001 2k, 3{
HIS-Q total score 34 28.01 (2.21) 35 35.88 (2.18) 71 41.11 (1.53) 30 49.24 (2.36) 15.83 <.0001 2#, 3#, 5{, 6k
HIS-Q Score
Total testosterone categories (n ¼ 172)
Overall F-test*
Pairwise comparison
(P value)‡
<300 ng/dL 300e500 ng/dL >500 ng/dL
n LS mean (SE) n LS mean (SE) n LS mean (SE) F P value
Sexual symptoms domain 68 51.31 (2.39) 55 45.08 (2.65) 45 35.08 (2.93) 9.21 .0002 2#, 3k
Libido subdomain 68 54.04 (2.42) 56 47.62 (2.66) 45 39.81 (2.97) 6.94 .0013 2{
Sexual function subdomain 68 49.26 (3.15) 55 43.75 (3.51) 47 31.52 (3.79) 6.56 .0018 2{
Energy symptoms domain 68 51.59 (2.95) 56 42.86 (3.25) 47 37.94 (3.55) 4.69 .0104 2k
Sleep symptoms domain 67 39.18 (2.31) 55 39.09 (2.54) 47 29.96 (2.75) 4.01 .0199 2k
Cognition symptoms domain 68 37.99 (2.06) 55 33.64 (2.29) 47 29.61 (2.47) 3.45 .0342 2k
Mood symptoms domain 68 36.71 (2.13) 55 33.77 (2.36) 47 27.89 (2.56) 3.55 .0310 2k
HIS-Q total score 67 43.67 (1.68) 54 38.78 (1.87) 45 32.15 (2.05) 9.43 .0001 2#
CGI-S ¼ Global ImpressioneSeverity; HIS-Q ¼ Hypogonadism Impact of Symptoms Questionnaire; LS ¼ least-squares; SE ¼ standard error.
kP < .05; {P < .001; #P < .0001.
*General linear model (PROC GLM). Pairwise comparisons between LS means were performed using the Scheffe test adjusting for multiple comparisons.
†Pairwise comparisons: 1 ¼ no or very mild vs mild symptoms; 2 ¼ no or very mild vs moderate symptoms; 3 ¼ no or very mild vs severe symptoms; 4 ¼ mild vs moderate symptoms; 5 ¼ mild vs severe
symptoms; 6 ¼ moderate vs severe symptoms.
‡Pairwise comparisons: 1 ¼ <300 vs 300e500 ng/dL; 2 ¼ <300 vs >500 ng/dL; 3 ¼ 300e500 vs >500 ng/dL.
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Table 5. Responsiveness and anchor-based interpretation: HIS-Q score change by concept-speciﬁc anchor question score change
HIS-Q score change
Change in anchor question
Overall F-test*
Pairwise comparison
(P value)†
Decline Stable Improved by 1 point
Improved by 2
points
n LS mean (SE) n LS mean (SE) n LS mean (SE) n LS mean (SE) F P value
Sexual symptoms domain by sexual
activity anchor
Baseline to week 6 29 8.00 (2.61) 65 1.48 (1.74) 42 11.14 (2.17) 18 33.33 (3.31) 36.46 <.0001 1‡, 2k, 3k, 4‡, 5k, 6k
Baseline to week 12 25 6.14 (2.97) 62 1.73 (1.88) 40 10.36 (2.35) 20 26.07 (3.32) 20.64 <.0001 2§, 3k, 4‡, 5k, 6‡
Sexual symptoms domain by overall
sexual function anchor
Baseline to week 6 30 9.88 (2.69) 54 2.91 (2.00) 41 8.54 (2.30) 29 24.88 (2.73) 28.76 <.0001 1‡, 2k, 3k, 5k, 6§
Baseline to week 12 23 6.06 (3.10) 63 0.96 (1.88) 27 8.60 (2.86) 34 21.64 (2.55) 20.22 <.0001 2‡, 3k, 5k, 6‡
Libido subdomain by libido anchor
Baseline to week 6 39 8.55 (2.22) 64 4.30 (1.73) 42 12.10 (2.13) 9 27.78 (4.61) 24.29 <.0001 1§, 2k, 3k, 4‡, 5k, 6‡
Baseline to week 12 34 3.68 (2.91) 68 1.23 (2.06) 33 8.59 (2.95) 13 25.00 (4.70) 10.38 <.0001 2‡, 3k, 5§, 6‡
Sexual function subdomain by erectile
function anchor
Baseline to week 6 31 1.21 (4.43) 79 4.11 (2.77) 26 14.66 (4.84) 19 21.05 (5.66) 4.40 .0054 3‡
Baseline to week 12 35 1.79 (3.71) 66 5.49 (2.70) 26 15.14 (4.30) 21 22.32 (4.79) 6.51 .0004 2‡, 3‡, 5‡
Sexual function subdomain by overall
sexual function anchor
Baseline to week 6 31 14.92 (3.81) 54 4.05 (2.89) 41 10.37 (3.31) 29 30.60 (3.94) 23.72 <.0001 1‡, 2k, 3k, 5k, 6‡
Baseline to week 12 24 7.81 (4.03) 63 0.69 (2.49) 27 14.81 (3.80) 34 26.65 (3.39) 19.16 <.0001 2‡, 3k, 4‡, 5k
Energy symptom domain by tiredness
anchor
Baseline to week 6 22 10.98 (4.32) 70 3.10 (2.42) 52 18.59 (2.81) 11 37.88 (6.10) 20.48 <.0001 1‡, 2k, 3k, 4§, 5k, 6‡
Baseline to week 12 26 9.94 (3.77) 56 5.65 (2.57) 49 20.24 (2.74) 16 46.35 (4.80) 33.38 <.0001 1§, 2k, 3k, 4‡, 5k, 6‡
Mood symptom domain by mood
anchor
Baseline to week 6 46 11.72 (1.87) 64 1.45 (1.58) 33 8.86 (2.20) 12 22.32 (3.65) 31.20 <.0001 1§, 2k, 3k, 4‡, 5k, 6‡
Baseline to week 12 37 8.78 (2.14) 59 1.03 (1.70) 36 6.75 (2.17) 16 21.88 (3.26) 23.36 <.0001 1‡, 2k, 3k, 5k, 6‡
Cognition symptom domain by
cognition anchor
Baseline to week 6 43 9.50 (2.15) 69 0.36 (1.69) 29 7.18 (2.61) 14 19.05 (3.76) 17.53 <.0001 1‡, 2k, 3k, 5§
Baseline to week 12 30 8.33 (2.95) 75 0.67 (1.86) 29 10.92 (3.00) 14 18.45 (4.31) 12.02 <.0001 2§, 3k, 4‡, 5‡
Sleep symptom domain by sleep
anchor
Baseline to week 6 51 8.50 (2.12) 58 2.16 (1.99) 39 9.83 (2.42) 6 31.94 (6.18) 19.47 <.0001 1‡, 2k, 3k, 5§, 6‡
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1746 Gelhorn et alResponder Deﬁnition
Responder deﬁnitions were deﬁned using anchor- and
distribution-based methods. Anchor-based estimates were ob-
tained from the mean scores for participants who improved by one
point on the anchor questions for each domain (Table 5). The
anchor-based and distribution-based responder estimates are
presented in Figure 1, as is the ﬁnal responder deﬁnition, which
was determined by triangulating across all estimates (sexual¼ 7.0;
libido¼ 8.3; sexual function¼ 12.5; energy ¼ 16.6; sleep¼ 8.3;
cognition ¼ 8.3; mood ¼ 7.0; Figure 1). Interpretation of the
HIS-Q total score is complex, and the psychometric support for
the contributing items and subscales varies; the responder deﬁ-
nition for the HIS-Q total score is 7.0 (Figure 1).DISCUSSION
The HIS-Q is a 28-item PRO instrument to assess changes in
hypogonadal symptoms in response to TRT. The present study
provides strong support for the psychometric properties of this
newly developed instrument including the reliability, validity,
and responsiveness in addition to information on the interpre-
tation of the HIS-Q. To our knowledge, this is the ﬁrst PRO
that has been speciﬁcally developed for use in populations of
hypogonadal men that comprehensively evaluates all the relevant
domains, as identiﬁed through direct input from patients.
The HIS-Q demonstrated good correlations with other in-
struments designed to measure relevant domains of interest
(eg, sexual, energy, mood, etc). These strong correlations and the
comprehensive nature of the instrument suggest that it might be
a useful end point in future studies evaluating TRT. The HIS-Q
had moderate correlations with testosterone levels. Correlations
between PRO and clinical measurements are often small to
moderate in magnitude; this is expected because the value of a
PRO measurement lies in gathering information from the patient
that cannot be assessed through clinical measurements or other
means.
It is important to note that the objective of this research was
not to establish expected TRT treatment effects or estimate ef-
fects sizes for the instrument, but to ensure that the selected
items performed appropriately for instrument ﬁnalization.
Because of the observational study design and cohort selected for
the present research (eg, many had relatively normal testosterone
levels at baseline because the study required a “maintenance”
group in which HIS-Q changes were not expected), reliable es-
timates of TRT treatment effects will need to be determined in
future well-controlled studies.
Although it is possible to calculate a total score for the HIS-Q,
this score should be carefully considered, adequately justiﬁed for
speciﬁc research contexts, and interpreted with caution. Quali-
tative work results suggest that hypogonadism is highly hetero-
geneous in the symptoms experienced5 and the psychometric
properties vary across different HIS-Q domains. The HIS-Q
domains measure distinct constructs and use of the compositeJ Sex Med 2016;13:1737e1749
Table 6. Responsiveness: HIS-Q score change by CGI-S score change
HIS-Q score change
CGI-S score change
Overall F-test* Pairwise
comparison
(P value)†
Decline (1) Stable (0) Improvement (1)
n LS mean (SE) n LS mean (SE) n LS mean (SE) F P value
Sexual symptoms domain
Baseline to week 2 13 7.69 (4.48) 76 0.52 (1.85) 55 8.31 (2.18) 6.71 .0016 1‡, 2‡
Baseline to week 12 13 3.02 (4.73) 57 0.63 (2.26) 73 11.99 (2.00) 10.57 <.0001 1§, 2‡
Libido subdomain
Baseline to week 2 13 3.21 (4.59) 78 2.14 (1.87) 55 5.61 (2.23) 1.70 .1861
Baseline to week 12 14 5.95 (4.81) 57 1.02 (2.38) 73 8.33 (2.11) 4.39 .0142 1‡
Sexual function subdomain
Baseline to week 2 13 11.06 (6.21) 78 0.08 (2.54) 55 10.34 (3.02) 6.25 .0025 1‡, 2‡
Baseline to week 12 14 4.02 (6.17) 58 0.54 (3.03) 73 14.64 (2.70) 8.67 .0003 1‡, 2‡
Energy symptoms domain
Baseline to week 2 13 7.69 (5.91) 80 7.40 (2.38) 55 11.82 (2.87) 4.43 .0136 2‡
Baseline to week 12 16 1.04 (6.25) 57 8.33 (3.31) 73 17.01 (2.93) 4.24 .0162 2‡
Sleep symptoms domain
Baseline to week 2 13 2.56 (4.27) 79 1.69 (1.73) 55 4.70 (2.08) 1.37 .2566
Baseline to week 12 16 2.08 (4.65) 57 2.78 (2.46) 72 7.75 (2.19) 2.34 .0997
Cognition symptoms domain
Baseline to week 2 13 2.56 (4.50) 80 0.10 (1.81) 55 3.18 (2.19) 0.93 .3952
Baseline to week 12 16 6.77 (4.38) 57 1.02 (2.32) 73 4.45 (2.05) 2.80 .0640
CGI-S ¼ Global ImpressioneSeverity; HIS-Q ¼ Hypogonadism Impact of Symptoms Questionnaire; LS ¼ least-squares; SE ¼ standard error.
‡P < .05; §P < .001.
*General linear model (PROC GLM). Pairwise comparisons between LS means were performed using the Scheffe test adjusting for multiple comparisons.
†Improvement vs Stable; 2: Improvement vs Decline; 3: Stable vs Decline.
Figure 1. Summary of distribution- and anchor-based estimates of clinically meaningful change for the Hypogonadism Impact of
Symptoms Questionnaire (HIS-Q).
J Sex Med 2016;13:1737e1749
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1748 Gelhorn et alHIS-Q total score as an end point might not capture treatment
effects precisely. Analyzing speciﬁc domains of interest is rec-
ommended over using the total score. The sexual domain, libido
and sexual function subdomains, and energy domain have the
strongest psychometric properties and are likely the best outcome
measurements for studies aiming to characterize TRT treatment
effects.
The longer 2-week recall period was selected for the HIS-Q
sexual domain because hypogonadal men often have lower
levels of sexual activity and interest; thus, a longer period is
appropriate to allow the opportunity for men to have relevant
sexual experiences on which they can report. Shorter 1-week
recall periods were selected for other domains. The recall periods
that were selected for the HIS-Q domains are intended to strike a
balance among accuracy of recall, respondent burden, and
consideration for an adequate opportunity to engage in activities
that form the basis for certain responses.
There were several limitations that should be noted. The eti-
ology of hypogonadism for each patient participating in the study
was not always known. In particular, the study team found that it
was difﬁcult to recruit patients with congenital secondary
hypogonadism and those who were untreated. In addition, the
men who participated in this study had testosterone levels that
were not as low as expected at baseline, although the study was
strengthened by the use of a central laboratory for the liquid
chromatographic and tandem mass spectrometric testosterone
testing. Moreover, some analyses in the present study (eg,
exploratory factor analysis) could have beneﬁted from a larger
sample. Future studies of larger samples of men with hypo-
gonadism will be used to further evaluate and conﬁrm the factor
structure of the HIS-Q. Future studies also will be aimed at
further examining the performance properties of the HIS-Q and
the relations of the instrument with clinical measurements in
samples of symptomatic hypogonadal men with unequivocally
low testosterone levels. It is important to note that the HIS-Q
was neither designed nor tested as a screener for hypogonadism
and its performance characteristics for this purpose are unknown.CONCLUSIONS
The HIS-Q, a newly developed PRO instrument for the
evaluation of hypogonadal symptoms, has demonstrated good
reliability, validity, and responsiveness. The measurement has
been developed in line with current Food and Drug Adminis-
tration PRO guidance, and the ﬁnal version of the measurement
can be incorporated into TRT clinical trials. A shorter version of
the instrument that lessens respondent burden and might be
useful in clinical practice is currently under development.
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